10x Genomics (TXG) Operating Expenses (2018 - 2026)

10x Genomics has disclosed Operating Expenses across 9 years of filings, most recently posting $132.1 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 39.06% year-over-year to $132.1 million; the TTM figure through Jun 2026 stood at $520.4 million (down 5.1% YoY), while the FY2025 annual figure was $504.9 million, down 17.1% from the prior year.
• Operating Expenses came in at $132.1 million for Q2 2026 at 10x Genomics, up from $123.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $190.3 million in Q3 2023 to a low of $95.0 million in Q2 2025.
• Average Operating Expenses over 5 years is $144.9 million, with a median of $145.4 million recorded in 2024.
• Year-over-year, Operating Expenses sank 34.94% in 2025 and soared 39.06% in 2026.
• Over 5 years, Operating Expenses stood at $142.5 million in 2022, then grew by 19.98% to $171.0 million in 2023, then decreased by 5.95% to $160.8 million in 2024, then retreated by 17.54% to $132.6 million in 2025, then decreased by 0.4% to $132.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $132.1 million in Q2 2026, $123.2 million in Q1 2026, and $132.6 million in Q4 2025.